Ming-Liang Ma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ming-Liang Ma has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Chuang-Sheng Hu
Shanghai Jiao Tong University
2 shared publications - Dan-Yun Lai
Shanghai Jiao Tong University
2 shared publications - Hua Li
Jiangsu Province Engineering Research Center of Development and Translation of Key Technologies for Chronic Disease Prevention and Control, Suzhou Vocational Health College, Suzhou, China
2 shared publications - Huan Qi
Shanghai Center for Systems Biomedicine, Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Jiao Tong University, Shanghai 200240, China
2 shared publications - Sheng-Ce Tao
Shanghai Center for Systems Biomedicine, Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China
2 shared publications - Shu-Juan Guo
Shanghai Center for Systems Biomedicine, Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Jiao Tong University, Shanghai, China
2 shared publications
Latest Publications
- Open Access
Systematic profiling of SARS-CoV-2 specific IgG epitopes at single amino acid resolution
SARS-CoV-2 specific IgG responses play critical roles for patients to recover from COVID-19, in-depth dissecting of the IgG responses on systems level is of great interest. Herein, we adopted a newly developed high-throughput epitope mapping technology (AbMap), analyzed 55 COVID-19 convalescent sera and 226 antibody samples enriched by specific proteins or peptides from these sera. We revealed three areas that are rich of IgG epitopes, two are on Spike protein but outside of RBD, and one is on Nucleocapsid protein. We identified 29 significant epitopes on Spike protein, from two of these significant epitopes, two critical epitope residues were found, i. e ., D936 and P1263, which are highly related to the infectivity of SARS-CoV-2 In summary, we provided the first global map of IgG binding epitopes for SARS-CoV-2 at single amino acid resolution. This map will facilitate the precise development of therapeutic antibodies and vaccines. HIGHLIGHTS: A map of SARS-CoV-2 specific IgG binding epitopes at single amino acid resolution Two areas outside of RBD that are rich of significant epitopes were identified One area rich of significant epitopes was determined on Nucleocapsid protein Two critical epitope residues (D936 and P1263) on Spike protein are highly related to the infectivity of SARS-CoV-2
Open AccessSystematic profiling of SARS-CoV-2 specific IgG epitopes at single amino acid resolution
SARS-CoV-2 specific IgG responses play critical roles for patients to recover from COVID-19, in-depth dissecting of the IgG responses on systems level is of great interest. Herein, we adopted a newly developed high-throughput epitope mapping technology (AbMap), analyzed 55 COVID-19 convalescent sera and 226 antibody samples enriched by specific proteins or peptides from these sera. We revealed three areas that are rich of IgG epitopes, two are on Spike protein but outside of RBD, and one is on Nucleocapsid protein. We identified 29 significant epitopes on Spike protein, from two of these significant epitopes, two critical epitope residues were found, i. e ., D936 and P1263, which are highly related to the infectivity of SARS-CoV-2 In summary, we provided the first global map of IgG binding epitopes for SARS-CoV-2 at single amino acid resolution. This map will facilitate the precise development of therapeutic antibodies and vaccines. HIGHLIGHTS: A map of SARS-CoV-2 specific IgG binding epitopes at single amino acid resolution Two areas outside of RBD that are rich of significant epitopes were identified One area rich of significant epitopes was determined on Nucleocapsid protein Two critical epitope residues (D936 and P1263) on Spike protein are highly related to the infectivity of SARS-CoV-2
- Open Access
Antibody binding epitope Mapping (AbMap) of two hundred antibodies in a single run
Epitope mapping is essential for the understanding how an antibody works. Given millions of antibodies short of epitope information, there is an urgent need for high-throughput epitope mapping. Here we combined a commercial phage displayed random peptide library of 10 9 diversity with next generation sequencing to develop A ntibody b inding epitope Map ping (AbMap) technology. Over two hundred antibodies were analyzed in a single test and epitopes were determined for >50% of them. Strikingly, the antibodies were able to recognize different proteins from multiple species with similar epitopes. We successfully identified the epitopes of 14 anti-PD-1 antibodies, including Sintilimab ( i.e. , L128, A129 and P130), and confirmed that the binding epitopes of Nivolumab and Sintilimab are very close to the binding interface of PD-1 and PD-L1. The predicted conformational epitopes of Pembrolizumab and Nivolumab are consistent with their antibody-antigen co-crystal structures. AbMap is the first technology enables high-throughput epitope mapping. Highlights: The first technology enables epitope mapping of two hundred antibodies in a single run Linear epitope was determined for >50% of the antibodies Distinct epitopes of 14 anti-PD-1 antibodies, including Sintilimab, were determined The predicted conformational epitopes of Pembrolizumab and Nivolumab are consistent with the known antibody-antigen co-crystal structures
Open AccessAntibody binding epitope Mapping (AbMap) of two hundred antibodies in a single run
Epitope mapping is essential for the understanding how an antibody works. Given millions of antibodies short of epitope information, there is an urgent need for high-throughput epitope mapping. Here we combined a commercial phage displayed random peptide library of 10 9 diversity with next generation sequencing to develop A ntibody b inding epitope Map ping (AbMap) technology. Over two hundred antibodies were analyzed in a single test and epitopes were determined for >50% of them. Strikingly, the antibodies were able to recognize different proteins from multiple species with similar epitopes. We successfully identified the epitopes of 14 anti-PD-1 antibodies, including Sintilimab ( i.e. , L128, A129 and P130), and confirmed that the binding epitopes of Nivolumab and Sintilimab are very close to the binding interface of PD-1 and PD-L1. The predicted conformational epitopes of Pembrolizumab and Nivolumab are consistent with their antibody-antigen co-crystal structures. AbMap is the first technology enables high-throughput epitope mapping. Highlights: The first technology enables epitope mapping of two hundred antibodies in a single run Linear epitope was determined for >50% of the antibodies Distinct epitopes of 14 anti-PD-1 antibodies, including Sintilimab, were determined The predicted conformational epitopes of Pembrolizumab and Nivolumab are consistent with the known antibody-antigen co-crystal structures